{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/alopecia-androgenetic-female/diagnosis/differential-diagnosis/","result":{"pageContext":{"chapter":{"id":"8ec69667-1bf4-5d04-8c65-48f0cca236b3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis","depth":2,"htmlHeader":"<!-- begin field 9a4d7b76-2943-4cb0-bd3d-9a139232b006 --><h2>What else might it be?</h2><!-- end field 9a4d7b76-2943-4cb0-bd3d-9a139232b006 -->","summary":"","htmlStringContent":"<!-- begin item 05ef22a9-5ed2-4593-a089-bd3e05cae70b --><!-- begin field 95288c62-3c0a-4a59-a130-b5964c130e75 --><ul><li><strong>Conditions that may present similarly which cause non-scarring alopecia include:</strong><ul><li><strong> </strong><strong>Telogen effluvium</strong> —<strong> </strong>the most common alternative diagnosis. <ul><li>Sudden and severe shedding may occur when a higher percentage of hairs are in the resting phase.</li><li>Shedding may follow significant events — it may occur up to 3 months after childbirth, severe infection, crash diets, or major surgery, or may be precipitated by some medications (for example antidepressants, anticoagulants, chemotherapy, oral contraceptives containing high levels of androgens, and hormone replacement therapy).</li><li>Usually scalp coverage is good, because more than half the hair must be lost before it is objectively apparent.</li><li>In the active phase, the <a class=\"topic-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/diagnosis/diagnosis-assessment/#pull-test\">pull test</a> may be positive. Later, regrowth with tapered short hairs may be seen.</li></ul></li><li><strong>Alopecia areata</strong> — characterised by diffuse, patchy hair shedding in sharply defined areas. It usually affects women over 40 years of age. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/alopecia-areata/\">Alopecia areata</a> for more information.</li><li><strong>Syphilis</strong> — characterized by patchy hair loss of the scalp and lateral eyebrows described as having a 'moth-eaten' appearance. These features usually persist for a few weeks and heal spontaneously with or without treatment. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/syphilis/\">Syphilis</a> for more information.</li><li><strong>Traction alopecia</strong> — such as from hair being persistently pulled back in styles like a ponytail or tight plaiting, or resulting from long-term use of hair rollers.</li><li><strong>Trichotillomania </strong>— a psychiatric condition in which people pull their hair out. It may be associated with obsessive-compulsive disorder and is more common in women than men. Hair loss is asymmetrical and has an unusual shape. Single or multiple areas can be affected, including eyebrows and eyelashes.</li><li><strong>Hair fragility from chemical application</strong>— such as bleaching.</li></ul></li><li><strong>Conditions that present with inflammation, papules, pustules, or scaling on the scalp, may indicate a scarring-type alopecia such as:</strong><ul><li><strong>Frontal fibrosing alopecia</strong> — hair loss affects the hair margin on the front of the scalp. It most commonly occurs in women who have gone through the menopause but can also occur in pre-menopausal women.</li><li><strong>Lichen planopilaris</strong> — a rare inflammatory condition usually affecting young adult women, that results in smooth, white patches, and progressive, permanent hair loss mainly on the scalp. At the edges of these patches there may be scale and redness around each hair follicle.</li><li><strong>Discoid lupus erythematosus</strong> — characterised by persistent scaly, disc-like plaques on the scalp, face, and ears that may cause violaceous or pink erythema, scarring, and hair loss.</li><li><strong>Dermatomyositis</strong> — a rare acquired inflammatory myopathy that is accompanied by an itchy skin rash. Although a scaly scalp with hair thinning may occur, it is usually characterised by reddish or bluish-purple patches, mostly on sun exposed areas of the body. </li><li><strong>Tinea capitis</strong> — typical features include an itchy, scaly scalp, with patchy, irregular hair loss. Lymphadenopathy (post-auricular and cervical) is often a sign of inflammatory tinea capitis and in more severe cases, erythema, pustules, permanent alopecia, and scarring of hair follicles may occur. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/fungal-skin-infection-scalp/\">Fungal skin infection - scalp</a> for more information.</li></ul></li><li><strong>Other underlying causes of hair loss include:</strong><ul><li><strong>Hypothyroidism </strong>and other endocrine disorders such as hyperprolactinaemia. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypothyroidism/\">Hypothyroidism</a> for more information.</li><li><strong>Iron deficiency</strong> and poor nutritional status.</li><li><strong>Drugs, </strong>including those:<ul><li>Implicated in telogen effluvium.</li><li>With an androgenic effect (such as anabolic steroids or progestogens).</li><li>With an antithyroid action (such as carbimazole).</li></ul></li><li><strong>Other systemic disease</strong>, such as a recent severe infection, systemic lupus erythematosus, or cancer.</li></ul></li></ul><!-- end field 95288c62-3c0a-4a59-a130-b5964c130e75 --><!-- end item 05ef22a9-5ed2-4593-a089-bd3e05cae70b -->","topic":{"id":"34cafa57-9383-5d80-b924-585fddfaf630","topicId":"ee168cae-489c-42c8-b09e-953c3911c90a","topicName":"Alopecia, androgenetic - female","slug":"alopecia-androgenetic-female","lastRevised":"Last revised in May 2016","chapters":[{"id":"ed7eb17b-bb56-55c8-93ed-c69fffb8ffb2","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"50eed0df-a1f0-5171-9181-43ae31f74c24","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a335b9ba-ae97-56fc-8f3c-67269d2cebee","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"423c1f05-2850-5fc3-9dfe-32260c543c30","slug":"changes","fullItemName":"Changes"},{"id":"98782d6b-86e0-52c6-874d-d38c3a7b8b43","slug":"update","fullItemName":"Update"}]},{"id":"c3b76113-c0a5-51d2-9626-e50262eb0b51","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"26174a6e-62fc-5925-bdc7-6dec1e3cc672","slug":"goals","fullItemName":"Goals"},{"id":"268ede25-aeb2-59d0-8650-e83fb2b7237c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d0de2e8e-6151-5970-b442-dab292556f28","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"beac34dd-51e9-51be-b40d-b68c2f22bab0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7238b814-3ad5-52e6-ad73-5c5e25e26035","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"16239c30-d709-5fbe-b215-e9181602c63f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3e8ded1e-bf8c-5ab8-bae3-0a3718045265","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2a41bf35-6b01-5146-9673-3480759cf2b2","slug":"definition","fullItemName":"Definition"},{"id":"3f9115db-2801-58d5-8b38-614632cc8518","slug":"causes","fullItemName":"Causes"},{"id":"22dc1f21-64e2-59d3-9248-27696a2ff2f3","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d994014c-2572-5645-8d46-23c950e5e12f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"b2055ae4-a6c4-5ea6-8abb-2ada0bfe997f","slug":"complications","fullItemName":"Complications"},{"id":"f6b263b5-2a9d-5889-b83a-31313b2349ba","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"c98a08a0-1460-5525-b53e-e7dd062f5271","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d05f7dc4-15b4-51a7-9040-1f13534d2bcd","slug":"diagnosis-assessment","fullItemName":"Diagnosis and assessment"},{"id":"5c4491cc-a38e-5798-9ea5-303e2514c88a","slug":"investigations","fullItemName":"Investigations"},{"id":"8ec69667-1bf4-5d04-8c65-48f0cca236b3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"dcc3e89f-77d3-55b8-96a0-7f18236d81ed","fullItemName":"Management","slug":"management","subChapters":[{"id":"84a05021-8d2e-500f-bac8-1152758fd81c","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"d947b9be-2aca-5db0-bde3-bd1288f9fe15","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"52c6980c-f25c-5733-a13e-000bf03bd936","slug":"topical-minoxidil-2percent-solution","fullItemName":"Topical minoxidil 2% solution"}]},{"id":"1f4c5c98-e1a3-5353-af89-7c80d4173e69","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"a13caaee-1053-53e3-9663-af5cdb6967c3","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c996db3c-f9be-5ca7-8fbf-6d8cc2a1dccf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"66cae4ab-b2ad-5800-b305-3061debc9954","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"4f39a0f4-1a5f-51fa-ad3f-0bc3472e20ae","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ebbfb681-3de5-545e-9479-c10e9c16eac3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"fb1f7555-0114-5914-8728-1ba58437da39","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2ef85d5b-cf19-51e6-b768-e1dfbdc625a0","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c98a08a0-1460-5525-b53e-e7dd062f5271","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"ffe49c4d-0e76-5f83-901f-ccfe1c9ad76c","slug":"basis-for-recommendation-b26","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 5d377fe1-3874-48d3-9536-3b207f60e689 --><h3>Basis for recommendation</h3><!-- end field 5d377fe1-3874-48d3-9536-3b207f60e689 -->","summary":null,"htmlStringContent":"<!-- begin item b268f133-0d21-41ac-8497-05855761a058 --><!-- begin field 467f1091-934f-433a-bd32-cf9460bd11bd --><p>The information on differential diagnoses is based on expert opinion in a European consensus guideline for the diagnostic evaluation of androgenetic alopecia in men, women, and adolescents [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Blume-Peytavi et al, 2010</a>], expert opinion in review articles for the diagnosis and management of androgenetic alopecia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Mirmirani, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Hillman and Blume-Peytavi, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Herskovitz et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Levy and Emer, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Torres et al, 2015</a>], and a British Medical Journal Best Practice article on androgenetic alopecia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">BMJ, 2015</a>].</p><!-- end field 467f1091-934f-433a-bd32-cf9460bd11bd --><!-- end item b268f133-0d21-41ac-8497-05855761a058 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}